Disease relevance of Ralgro

• Thus, for the first time, the bioactivity of coumestrol and zearalanol in preventing bone loss has been demonstrated in a well-recognized model of postmenopausal bone loss [1].
• Treatment of ovariectomized female rats daily with 1.5 or 2 mg P-1496/kg body weight resulted in marked increases in the concentrations of serum triglycerides associated with the very low density lipoprotein (VLDL) fraction [2].

Psychiatry related information on Ralgro

• Treatment of castrate males with diethylstilbestrol (DES) or zearalenol (P-1496) during the critical period was incapable of restoring development of normal male levels of HCLA sites [3].

High impact information on Ralgro

• In the studies of coumestrol and zearalanol, the rats were allocated to a control group, a phytoestrogen-treated group (1.5 micromol coumestrol or 3.1 mmol zearalanol twice per week, intramuscular) or, in the coumestrol study, an estrogen-treated group (28.1 nmol, intramuscular) [1].
• Unlike the growth response, ODC dose-response studies showed zearalanol to be about 20-fold more effective than zearalenone [4].
• In the study, uterus, liver and muscle tissue from 24 cycling heifers were taken after the animals were treated either with Melengestrol Acetate (MGA), Finaplix-H (200 mg Trenbolone Acetate) or Ralgro (36 mg Zeranol) for 56 days [5].
• Zearanol metabolism by subcellular fractions from lamb liver [6].
• In the present study, the binding characteristics of [3H]zearalanol (P-1496) to different classes of sites including [1] the oestrogen receptor, [2] the higher capacity lower affinity (HCLA) sites, [3] the antioestrogen sites and [4] a new class of binding sites apparently specific for P-1496 were examined in rat liver [2].

Analytical, diagnostic and therapeutic context of Ralgro

• Compared with the control group, rats receiving coumestrol and zearalanol had significantly reduced bone loss at all sites measured [1].
• Reimplantation did improve (P less than .05) feed utilization in Ralgro implanted steers, however [7].
• Radioimmunoassay of the anabolic agent zeranol. III. Zeranol concentrations in the faeces of steers implanted with zeranol (Ralgro) [8].
• Analysis of the binding by sucrose density gradient centrifugation confirmed that P-1496 binds to the oestrogen receptor but not to the higher capacity lower affinity sites for oestradiol-17 beta [2].

References